Skip to main content
Top
Published in: Cancer and Metastasis Reviews 2/2022

02-04-2022 | Metastasis | Non-Thematic Review

Nanotechnology-aided advancement in the combating of cancer metastasis

Authors: Leela Rani Avula, Piotr Grodzinski

Published in: Cancer and Metastasis Reviews | Issue 2/2022

Login to get access

Abstract

Cancer, especially when it has metastasized to different locations in the body, is notoriously difficult to treat. Metastatic cancer accounts for most cancer deaths and thus remains an enormous challenge. During the metastasis process, cancer cells negotiate a series of steps termed the “metastatic cascadeˮ that offer potential for developing anti-metastatic therapy strategies. Currently available conventional treatment and diagnostic methods addressing metastasis come with their own pitfalls and roadblocks. In this contribution, we comprehensively discuss the potential improvements that nanotechnology-aided approaches are able to bring, either alone or in combination with the existing conventional techniques, to the identification and treatment of metastatic disease. We tie specific nanotechnology-aided strategies to the complex biology of the different steps of the metastatic cascade in order to open up new avenues for fine-tuned targeting and development of anti-metastatic agents designed specifically to prevent or mitigate the metastatic outgrowth of cancer. We also present a viewpoint on the progress of translation of nanotechnology into cancer metastasis patient care.
Appendix
Available only for authorised users
Literature
1.
go back to reference Caswell, D. R., & Swanton, C. (2017). The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Medicine, 15(1), 133.PubMedPubMedCentralCrossRef Caswell, D. R., & Swanton, C. (2017). The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Medicine, 15(1), 133.PubMedPubMedCentralCrossRef
2.
go back to reference Lüönd, F., Tiede, S., & Christofori, G. (2021). Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British Journal of Cancer, 125(2), 164–175.PubMedPubMedCentralCrossRef Lüönd, F., Tiede, S., & Christofori, G. (2021). Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British Journal of Cancer, 125(2), 164–175.PubMedPubMedCentralCrossRef
3.
go back to reference Saxena, M., Christofori G. (2013). Rebuilding cancer metastasis in the mouse. Molecular Oncology, 7. Saxena, M., Christofori G. (2013). Rebuilding cancer metastasis in the mouse. Molecular Oncology, 7.
4.
go back to reference van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research, 728(1–2), 23–34.PubMedPubMedCentralCrossRef van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research, 728(1–2), 23–34.PubMedPubMedCentralCrossRef
6.
go back to reference Anderson, R. L., et al. (2019). A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), 185–204.PubMedCrossRef Anderson, R. L., et al. (2019). A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), 185–204.PubMedCrossRef
8.
go back to reference Jayne, D. G. (2003). The molecular biology of peritoneal carcinomatosis from gastrointestinal cancer. Ann Acad Med Singap, 32(2), 219–225.PubMed Jayne, D. G. (2003). The molecular biology of peritoneal carcinomatosis from gastrointestinal cancer. Ann Acad Med Singap, 32(2), 219–225.PubMed
9.
go back to reference Langley, R. R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128(11), 2527–2535.PubMedPubMedCentralCrossRef Langley, R. R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128(11), 2527–2535.PubMedPubMedCentralCrossRef
10.
go back to reference Mollica, H., et al. (2019). Two-Channel Compartmentalized Microfluidic Chip for Real-Time Monitoring of the Metastatic Cascade. ACS Biomaterials Science & Engineering, 5(9), 4834–4843.CrossRef Mollica, H., et al. (2019). Two-Channel Compartmentalized Microfluidic Chip for Real-Time Monitoring of the Metastatic Cascade. ACS Biomaterials Science & Engineering, 5(9), 4834–4843.CrossRef
11.
12.
go back to reference Neben, K., et al. (2008). Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. Deutsches Ärzteblatt International, 105(43), 733–740.PubMedPubMedCentral Neben, K., et al. (2008). Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. Deutsches Ärzteblatt International, 105(43), 733–740.PubMedPubMedCentral
13.
go back to reference Visentin, S., et al. (2020). Targeting Tumour Metastasis: The Emerging Role of Nanotechnology. Current Medicinal Chemistry, 27(8), 1367–1381.PubMedCrossRef Visentin, S., et al. (2020). Targeting Tumour Metastasis: The Emerging Role of Nanotechnology. Current Medicinal Chemistry, 27(8), 1367–1381.PubMedCrossRef
14.
go back to reference Park, G. T., & Choi, K. C. (2016). Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy. Oncotarget, 7(36), 58684–58695.PubMedPubMedCentralCrossRef Park, G. T., & Choi, K. C. (2016). Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy. Oncotarget, 7(36), 58684–58695.PubMedPubMedCentralCrossRef
15.
go back to reference Wu, Q., et al. (2014). Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Letters, 347(2), 159–166.PubMedCrossRef Wu, Q., et al. (2014). Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Letters, 347(2), 159–166.PubMedCrossRef
16.
go back to reference Perez-Herrero, E., & Fernandez-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 93, 52–79.PubMedCrossRef Perez-Herrero, E., & Fernandez-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 93, 52–79.PubMedCrossRef
17.
go back to reference Ali, E. S., et al. (2021). Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. Seminars in Cancer Biology, 69, 52–68.PubMedCrossRef Ali, E. S., et al. (2021). Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. Seminars in Cancer Biology, 69, 52–68.PubMedCrossRef
18.
go back to reference Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760.PubMedCrossRef Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760.PubMedCrossRef
19.
go back to reference Mocan, T., et al. (2017). Carbon nanotubes as anti-bacterial agents. Cellular and Molecular Life Sciences, 74(19), 3467–3479.PubMedCrossRef Mocan, T., et al. (2017). Carbon nanotubes as anti-bacterial agents. Cellular and Molecular Life Sciences, 74(19), 3467–3479.PubMedCrossRef
20.
go back to reference Mocan, T., et al. (2015). In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism. Journal of Cancer, 6(6), 583–592.PubMedPubMedCentralCrossRef Mocan, T., et al. (2015). In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism. Journal of Cancer, 6(6), 583–592.PubMedPubMedCentralCrossRef
21.
go back to reference Li, Y., et al. (2018). Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities. Nanomaterials (Basel), 8(6). Li, Y., et al. (2018). Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities. Nanomaterials (Basel)8(6).
22.
go back to reference van der Meel, R., Lammers, T., & Hennink, W. E. (2017). Cancer nanomedicines: Oversold or underappreciated? Expert Opinion on Drug Delivery, 14(1), 1–5.PubMedCrossRef van der Meel, R., Lammers, T., & Hennink, W. E. (2017). Cancer nanomedicines: Oversold or underappreciated? Expert Opinion on Drug Delivery, 14(1), 1–5.PubMedCrossRef
24.
go back to reference Lungu, II, et al. (2019). Nanobiomaterials Used in Cancer Therapy: An Up-To-Date Overview. Molecules, 24(19). Lungu, II, et al. (2019). Nanobiomaterials Used in Cancer Therapy: An Up-To-Date Overview. Molecules, 24(19).
26.
go back to reference Stover, T., & Kester, M. (2003). Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. Journal of Pharmacology and Experimental Therapeutics, 307(2), 468–475.PubMedCrossRef Stover, T., & Kester, M. (2003). Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. Journal of Pharmacology and Experimental Therapeutics, 307(2), 468–475.PubMedCrossRef
27.
go back to reference Choi, S. J., & Choy, J. H. (2011). Layered double hydroxide nanoparticles as target-specific delivery carriers: Uptake mechanism and toxicity. Nanomedicine (London, England), 6(5), 803–814.CrossRef Choi, S. J., & Choy, J. H. (2011). Layered double hydroxide nanoparticles as target-specific delivery carriers: Uptake mechanism and toxicity. Nanomedicine (London, England), 6(5), 803–814.CrossRef
28.
go back to reference Harrison, E. B., et al. (2020). A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. Cancer Research, 80(22), 4972–4985.PubMedPubMedCentralCrossRef Harrison, E. B., et al. (2020). A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. Cancer Research, 80(22), 4972–4985.PubMedPubMedCentralCrossRef
29.
go back to reference Xu, M., et al. (2021). Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy. Nature Communications, 12(1), 3187.PubMedPubMedCentralCrossRef Xu, M., et al. (2021). Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy. Nature Communications, 12(1), 3187.PubMedPubMedCentralCrossRef
30.
go back to reference Kaluzova, M., et al. (2015). Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget, 6(11), 8788–8806.PubMedPubMedCentralCrossRef Kaluzova, M., et al. (2015). Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget, 6(11), 8788–8806.PubMedPubMedCentralCrossRef
31.
go back to reference Liu, R., et al. (2019). Theranostic nanoparticles with tumor-specific enzyme-triggered size reduction and drug release to perform photothermal therapy for breast cancer treatment. Acta Pharm Sin B, 9(2), 410–420.PubMedCrossRef Liu, R., et al. (2019). Theranostic nanoparticles with tumor-specific enzyme-triggered size reduction and drug release to perform photothermal therapy for breast cancer treatment. Acta Pharm Sin B, 9(2), 410–420.PubMedCrossRef
32.
go back to reference Luo, Z., Dai, Y., & Gao, H. (2019). Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B, 9(6), 1099–1112.PubMedPubMedCentralCrossRef Luo, Z., Dai, Y., & Gao, H. (2019). Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B, 9(6), 1099–1112.PubMedPubMedCentralCrossRef
33.
go back to reference Liu, R., et al. (2018). Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. Journal of Controlled Release, 278, 127–139.PubMedCrossRef Liu, R., et al. (2018). Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. Journal of Controlled Release, 278, 127–139.PubMedCrossRef
34.
go back to reference Qin, L., & Gao, H. (2019). The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment. Asian Journal of Pharmaceutical Sciences, 14(4), 380–390.PubMedCrossRef Qin, L., & Gao, H. (2019). The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment. Asian Journal of Pharmaceutical Sciences, 14(4), 380–390.PubMedCrossRef
35.
go back to reference Zhang, W., et al. (2020). The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharmaceutica Sinica B, 10(11), 2037–2053.PubMedPubMedCentralCrossRef Zhang, W., et al. (2020). The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharmaceutica Sinica B, 10(11), 2037–2053.PubMedPubMedCentralCrossRef
36.
go back to reference Hu, C., et al. (2018). Coadministration of iRGD with Multistage Responsive Nanoparticles Enhanced Tumor Targeting and Penetration Abilities for Breast Cancer Therapy. ACS Applied Materials & Interfaces, 10(26), 22571–22579.CrossRef Hu, C., et al. (2018). Coadministration of iRGD with Multistage Responsive Nanoparticles Enhanced Tumor Targeting and Penetration Abilities for Breast Cancer Therapy. ACS Applied Materials & Interfaces, 10(26), 22571–22579.CrossRef
37.
go back to reference Tran, M. A., et al. (2008). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research, 14(11), 3571–3581.PubMedCrossRef Tran, M. A., et al. (2008). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research, 14(11), 3571–3581.PubMedCrossRef
38.
go back to reference Chen, J., et al. (2014). Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. International Journal of Nanomedicine, 9, 3403–3411.PubMedPubMedCentral Chen, J., et al. (2014). Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. International Journal of Nanomedicine, 9, 3403–3411.PubMedPubMedCentral
40.
go back to reference Del Bufalo, D., et al. (2006). Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Research, 66(11), 5549–5554.PubMedCrossRef Del Bufalo, D., et al. (2006). Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Research, 66(11), 5549–5554.PubMedCrossRef
41.
go back to reference Yu, H., et al. (2020). Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus. Biomater Sci, 8(1), 325–332.PubMedCrossRef Yu, H., et al. (2020). Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus. Biomater Sci, 8(1), 325–332.PubMedCrossRef
42.
go back to reference Clarke, M. F., et al. (2006). Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research, 66(19), 9339–9344.PubMedCrossRef Clarke, M. F., et al. (2006). Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research, 66(19), 9339–9344.PubMedCrossRef
43.
go back to reference Dreesen, O., & Brivanlou, A. H. (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev, 3(1), 7–17.PubMedCrossRef Dreesen, O., & Brivanlou, A. H. (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev, 3(1), 7–17.PubMedCrossRef
44.
go back to reference Li, F., et al. (2007). Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Research, 17(1), 3–14.PubMedCrossRef Li, F., et al. (2007). Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Research, 17(1), 3–14.PubMedCrossRef
45.
go back to reference Baumann, M., Krause, M., & Hill, R. (2008). Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 8(7), 545–554.PubMedCrossRef Baumann, M., Krause, M., & Hill, R. (2008). Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 8(7), 545–554.PubMedCrossRef
46.
go back to reference Reda, A., Hosseiny, S., & El-Sherbiny, I. M. (2019). Next-generation nanotheranostics targeting cancer stem cells. Nanomedicine, 14(18), 2487–2514.PubMedCrossRef Reda, A., Hosseiny, S., & El-Sherbiny, I. M. (2019). Next-generation nanotheranostics targeting cancer stem cells. Nanomedicine, 14(18), 2487–2514.PubMedCrossRef
47.
go back to reference Zuo, Z. Q., et al. (2016). Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-beta signaling pathway inhibition. Biomaterials, 82, 48–59.PubMedCrossRef Zuo, Z. Q., et al. (2016). Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-beta signaling pathway inhibition. Biomaterials, 82, 48–59.PubMedCrossRef
48.
go back to reference Liu, D., et al. (2020). Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics, 10(3), 1181–1196.PubMedPubMedCentralCrossRef Liu, D., et al. (2020). Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics, 10(3), 1181–1196.PubMedPubMedCentralCrossRef
49.
go back to reference Wang, M., et al. (2016). Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. Journal of Controlled Release, 230, 26–33.PubMedCrossRef Wang, M., et al. (2016). Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. Journal of Controlled Release, 230, 26–33.PubMedCrossRef
50.
go back to reference Shen, S., et al. (2021). A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nature Nanotechnology, 16(1), 104–113.PubMedCrossRef Shen, S., et al. (2021). A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nature Nanotechnology, 16(1), 104–113.PubMedCrossRef
51.
go back to reference Lang, T., et al. (2019). Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer. Adv Mater, 31(5), e1806202. Lang, T., et al. (2019). Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer. Adv Mater31(5), e1806202.
52.
go back to reference Mahira, S., et al. (2019). Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomedicine & Pharmacotherapy, 110, 803–817.CrossRef Mahira, S., et al. (2019). Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomedicine & Pharmacotherapy, 110, 803–817.CrossRef
53.
go back to reference Kaushik, N. K., et al. (2016). Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT. Biomaterials, 87, 118–130.PubMedCrossRef Kaushik, N. K., et al. (2016). Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT. Biomaterials, 87, 118–130.PubMedCrossRef
54.
go back to reference Liu, Y., et al. (2015). Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nature Communications, 6(1), 5988.PubMedCrossRef Liu, Y., et al. (2015). Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nature Communications, 6(1), 5988.PubMedCrossRef
55.
go back to reference Petersburg, J. R., et al. (2018). Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells. ACS Nano, 12(7), 6563–6576.PubMedPubMedCentralCrossRef Petersburg, J. R., et al. (2018). Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells. ACS Nano, 12(7), 6563–6576.PubMedPubMedCentralCrossRef
56.
go back to reference Kang, T.-W., et al. (2015). Mica Nanoparticle, STB-HO Eliminates the Human Breast Carcinoma Cells by Regulating the Interaction of Tumor with its Immune Microenvironment. Scientific Reports, 5(1), 17515.PubMedPubMedCentralCrossRef Kang, T.-W., et al. (2015). Mica Nanoparticle, STB-HO Eliminates the Human Breast Carcinoma Cells by Regulating the Interaction of Tumor with its Immune Microenvironment. Scientific Reports, 5(1), 17515.PubMedPubMedCentralCrossRef
57.
go back to reference Yazdi, M. H., et al. (2012). The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittel-Forschung, 62(11), 525–531.PubMed Yazdi, M. H., et al. (2012). The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittel-Forschung, 62(11), 525–531.PubMed
58.
go back to reference Rao, L., et al. (2020). Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. Advanced Materials, 32(47), 2004853.CrossRef Rao, L., et al. (2020). Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. Advanced Materials, 32(47), 2004853.CrossRef
59.
go back to reference Liu, X., et al., Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials, 2020. 230: p. 119649. Liu, X., et al., Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials, 2020. 230: p. 119649.
60.
go back to reference Yang, X., et al. (2019). Tumor Microenvironment-Responsive Dual Drug Dimer-Loaded PEGylated Bilirubin Nanoparticles for Improved Drug Delivery and Enhanced Immune-Chemotherapy of Breast Cancer. Advanced Functional Materials, 29(32), 1901896.CrossRef Yang, X., et al. (2019). Tumor Microenvironment-Responsive Dual Drug Dimer-Loaded PEGylated Bilirubin Nanoparticles for Improved Drug Delivery and Enhanced Immune-Chemotherapy of Breast Cancer. Advanced Functional Materials, 29(32), 1901896.CrossRef
61.
go back to reference Kuai, R., et al., Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Science Advances, 2018. 4(4): p. eaao1736. Kuai, R., et al., Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Science Advances, 2018. 4(4): p. eaao1736.
62.
go back to reference Lu, J., et al. (2018). Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano, 12(11), 11041–11061.PubMedPubMedCentralCrossRef Lu, J., et al. (2018). Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano, 12(11), 11041–11061.PubMedPubMedCentralCrossRef
63.
go back to reference Li, T. F., et al. (2019). Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy. Acta Biomaterialia, 86, 381–394.PubMedCrossRef Li, T. F., et al. (2019). Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy. Acta Biomaterialia, 86, 381–394.PubMedCrossRef
64.
go back to reference Chen, Q., et al. (2016). Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications, 7(1), 13193.PubMedPubMedCentralCrossRef Chen, Q., et al. (2016). Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications, 7(1), 13193.PubMedPubMedCentralCrossRef
65.
go back to reference Lu, Q., et al. (2019). Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. Journal of Materials Chemistry B, 7(15), 2499–2511.PubMedCrossRef Lu, Q., et al. (2019). Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. Journal of Materials Chemistry B, 7(15), 2499–2511.PubMedCrossRef
66.
go back to reference Sun, W., et al., Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer. Biomaterials, 2019. 217: p. 119264. Sun, W., et al., Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer. Biomaterials, 2019. 217: p. 119264.
67.
go back to reference Yu, W., et al., Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis. Biomaterials, 2019. 217: p. 119309. Yu, W., et al., Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis. Biomaterials, 2019. 217: p. 119309.
68.
go back to reference Liu, R., et al. (2020). Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. Journal of Controlled Release, 321, 589–601.PubMedCrossRef Liu, R., et al. (2020). Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. Journal of Controlled Release, 321, 589–601.PubMedCrossRef
69.
go back to reference Liu, R., et al. (2019). Linear Chimeric Triblock Molecules Self-Assembled Micelles with Controllably Transformable Property to Enhance Tumor Retention for Chemo-Photodynamic Therapy of Breast Cancer. Advanced Functional Materials, 29(23), 1808462.CrossRef Liu, R., et al. (2019). Linear Chimeric Triblock Molecules Self-Assembled Micelles with Controllably Transformable Property to Enhance Tumor Retention for Chemo-Photodynamic Therapy of Breast Cancer. Advanced Functional Materials, 29(23), 1808462.CrossRef
70.
go back to reference Gao, F., et al., Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. Biomaterials, 2020. 230: p. 119635. Gao, F., et al., Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. Biomaterials, 2020. 230: p. 119635.
71.
go back to reference Liu, D., et al. (2019). Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Nano Letters, 19(10), 6964–6976.PubMedCrossRef Liu, D., et al. (2019). Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Nano Letters, 19(10), 6964–6976.PubMedCrossRef
72.
go back to reference Nayak, A., et al. (2019). Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation. Cellular Oncology (Dordrecht), 42(2), 157–171.CrossRef Nayak, A., et al. (2019). Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation. Cellular Oncology (Dordrecht), 42(2), 157–171.CrossRef
73.
go back to reference Guo, R., et al. (2019). Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Advanced Science, 6(9), 1801885.PubMedPubMedCentralCrossRef Guo, R., et al. (2019). Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Advanced Science, 6(9), 1801885.PubMedPubMedCentralCrossRef
74.
go back to reference Luo, L., et al. (2020). Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis. Journal of Controlled Release, 318, 124–135.PubMedCrossRef Luo, L., et al. (2020). Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis. Journal of Controlled Release, 318, 124–135.PubMedCrossRef
75.
go back to reference Ding, F., et al. (2020). Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis. Nanoscale Horiz, 5(6), 999–1015.PubMedCrossRef Ding, F., et al. (2020). Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis. Nanoscale Horiz, 5(6), 999–1015.PubMedCrossRef
76.
go back to reference Liu, J., et al. (2019). Enhanced Primary Tumor Penetration Facilitates Nanoparticle Draining into Lymph Nodes after Systemic Injection for Tumor Metastasis Inhibition. ACS Nano, 13(8), 8648–8658.PubMedCrossRef Liu, J., et al. (2019). Enhanced Primary Tumor Penetration Facilitates Nanoparticle Draining into Lymph Nodes after Systemic Injection for Tumor Metastasis Inhibition. ACS Nano, 13(8), 8648–8658.PubMedCrossRef
77.
go back to reference Cheng, J., et al., Nanotechnology-Assisted Isolation and Analysis of Circulating Tumor Cells on Microfluidic Devices. Micromachines (Basel), 2020. 11(8). Cheng, J., et al., Nanotechnology-Assisted Isolation and Analysis of Circulating Tumor Cells on Microfluidic Devices. Micromachines (Basel), 2020. 11(8).
78.
go back to reference Izadi, S., et al. (2020). Codelivery of HIF-1alpha siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression. Pharmaceutical Research, 37(10), 196.PubMedCrossRef Izadi, S., et al. (2020). Codelivery of HIF-1alpha siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression. Pharmaceutical Research, 37(10), 196.PubMedCrossRef
79.
go back to reference Ye, H., et al. (2019). Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials, 206, 1–12.PubMedCrossRef Ye, H., et al. (2019). Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials, 206, 1–12.PubMedCrossRef
80.
go back to reference Morad, S. A., et al. (2016). Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells. Cancer Letters, 376(2), 199–204.PubMedCrossRef Morad, S. A., et al. (2016). Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells. Cancer Letters, 376(2), 199–204.PubMedCrossRef
81.
go back to reference Krishnamurthy, K., et al. (2008). Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Research, 10(6), R106.PubMedPubMedCentralCrossRef Krishnamurthy, K., et al. (2008). Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Research, 10(6), R106.PubMedPubMedCentralCrossRef
82.
go back to reference Zhu, Y., et al. (2015). Enhanced Anti-Metastatic Activity of Etoposide Using Layered Double Hydroxide Nano Particles. Journal of Biomedical Nanotechnology, 11(12), 2158–2168.PubMedCrossRef Zhu, Y., et al. (2015). Enhanced Anti-Metastatic Activity of Etoposide Using Layered Double Hydroxide Nano Particles. Journal of Biomedical Nanotechnology, 11(12), 2158–2168.PubMedCrossRef
83.
go back to reference Luo, G., et al. (2010). LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. International Journal of Pharmaceutics, 385(1–2), 150–156.PubMedCrossRef Luo, G., et al. (2010). LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. International Journal of Pharmaceutics, 385(1–2), 150–156.PubMedCrossRef
84.
go back to reference Zhao, L., et al. (2020). Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. Journal of Controlled Release, 318, 1–15.PubMedCrossRef Zhao, L., et al. (2020). Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. Journal of Controlled Release, 318, 1–15.PubMedCrossRef
85.
go back to reference Peiris, P. M., et al. (2015). Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis. Journal of Pharmaceutical Sciences, 104(8), 2600–2610.PubMedCrossRef Peiris, P. M., et al. (2015). Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis. Journal of Pharmaceutical Sciences, 104(8), 2600–2610.PubMedCrossRef
86.
go back to reference Sun, W., et al. (2019). Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis. ACS Nano, 13(7), 7556–7567.PubMedCrossRef Sun, W., et al. (2019). Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis. ACS Nano, 13(7), 7556–7567.PubMedCrossRef
87.
go back to reference Bai, S. B., et al. (2020). Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer. Nanomedicine (London, England), 15(9), 833–849.CrossRef Bai, S. B., et al. (2020). Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer. Nanomedicine (London, England), 15(9), 833–849.CrossRef
88.
go back to reference Chen, S.-H., et al. (2020). Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. Journal of Materials Chemistry B, 8(17), 3789–3800.PubMedCrossRef Chen, S.-H., et al. (2020). Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. Journal of Materials Chemistry B, 8(17), 3789–3800.PubMedCrossRef
89.
go back to reference Kraljevic, S. and K. Pavelic, Navigare necessere est. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery. EMBO Rep, 2005. 6(8): p. 695–700. Kraljevic, S. and K. Pavelic, Navigare necessere est. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery. EMBO Rep, 2005. 6(8): p. 695–700.
90.
go back to reference Zhou, Y., et al. (2020). Targeted Delivery of Secretory Promelittin via Novel Poly(lactone-co-β-amino ester) Nanoparticles for Treatment of Breast Cancer Brain Metastases. Advanced Science, 7(5), 1901866.PubMedPubMedCentralCrossRef Zhou, Y., et al. (2020). Targeted Delivery of Secretory Promelittin via Novel Poly(lactone-co-β-amino ester) Nanoparticles for Treatment of Breast Cancer Brain Metastases. Advanced Science, 7(5), 1901866.PubMedPubMedCentralCrossRef
91.
go back to reference Juthani, R., et al. (2020). Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 26(1), 147–158.PubMedCrossRef Juthani, R., et al. (2020). Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 26(1), 147–158.PubMedCrossRef
92.
go back to reference Huo, D., et al. (2019). Eradication of unresectable liver metastasis through induction of tumour specific energy depletion. Nature Communications, 10(1), 3051.PubMedPubMedCentralCrossRef Huo, D., et al. (2019). Eradication of unresectable liver metastasis through induction of tumour specific energy depletion. Nature Communications, 10(1), 3051.PubMedPubMedCentralCrossRef
94.
go back to reference Kaps, L. and D. Schuppan, Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells, 2020. 9(9). Kaps, L. and D. Schuppan, Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells, 2020. 9(9).
95.
go back to reference Li, Y. J., et al. (2020). Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. Journal of Controlled Release, 320, 105–111.PubMedCrossRef Li, Y. J., et al. (2020). Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. Journal of Controlled Release, 320, 105–111.PubMedCrossRef
96.
go back to reference Yin, F., et al., Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. Nanomedicine, 2020. 23: p. 102085. Yin, F., et al., Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. Nanomedicine, 2020. 23: p. 102085.
97.
go back to reference Kievit, F. M., et al. (2012). Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano, 6(3), 2591–2601.PubMedPubMedCentralCrossRef Kievit, F. M., et al. (2012). Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano, 6(3), 2591–2601.PubMedPubMedCentralCrossRef
98.
go back to reference Li, J., et al. (2014). A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano, 8(10), 9925–9940.PubMedCrossRef Li, J., et al. (2014). A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano, 8(10), 9925–9940.PubMedCrossRef
99.
go back to reference Patil, R., et al. (2015). MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: Nanoclinic in the brain. ACS Nano, 9(5), 5594–5608.PubMedPubMedCentralCrossRef Patil, R., et al. (2015). MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: Nanoclinic in the brain. ACS Nano, 9(5), 5594–5608.PubMedPubMedCentralCrossRef
100.
go back to reference Sundstrom, T., et al. (2013). Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Research, 73(8), 2445–2456.PubMedCrossRef Sundstrom, T., et al. (2013). Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Research, 73(8), 2445–2456.PubMedCrossRef
101.
go back to reference Weinstein, J. S., et al. (2010). Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. Journal of Cerebral Blood Flow and Metabolism, 30(1), 15–35.PubMedCrossRef Weinstein, J. S., et al. (2010). Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. Journal of Cerebral Blood Flow and Metabolism, 30(1), 15–35.PubMedCrossRef
103.
go back to reference Li, K., Nejadnik, H., & Daldrup-Link, H. E. (2017). Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. Drug Discovery Today, 22(9), 1421–1429.PubMedPubMedCentralCrossRef Li, K., Nejadnik, H., & Daldrup-Link, H. E. (2017). Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. Drug Discovery Today, 22(9), 1421–1429.PubMedPubMedCentralCrossRef
104.
go back to reference Rajkumar, V., et al. (2015). Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. British Journal of Cancer, 112(12), 1882–1887.PubMedPubMedCentralCrossRef Rajkumar, V., et al. (2015). Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. British Journal of Cancer, 112(12), 1882–1887.PubMedPubMedCentralCrossRef
105.
go back to reference Chen, F., et al., Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles. Sci Adv, 2019. 5(12): p. eaax5208. Chen, F., et al., Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles. Sci Adv, 2019. 5(12): p. eaax5208.
106.
go back to reference Diocou, S., et al. (2017). [(18)F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model. Science and Reports, 7(1), 946.CrossRef Diocou, S., et al. (2017). [(18)F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model. Science and Reports, 7(1), 946.CrossRef
107.
go back to reference Liu, T. W., et al. (2013). Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano, 7(5), 4221–4232.PubMedPubMedCentralCrossRef Liu, T. W., et al. (2013). Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano, 7(5), 4221–4232.PubMedPubMedCentralCrossRef
108.
go back to reference Parchur, A. K., et al. (2018). Vascular Interventional Radiology-Guided Photothermal Therapy of Colorectal Cancer Liver Metastasis with Theranostic Gold Nanorods. ACS Nano, 12(7), 6597–6611.PubMedPubMedCentralCrossRef Parchur, A. K., et al. (2018). Vascular Interventional Radiology-Guided Photothermal Therapy of Colorectal Cancer Liver Metastasis with Theranostic Gold Nanorods. ACS Nano, 12(7), 6597–6611.PubMedPubMedCentralCrossRef
109.
go back to reference Chen, Q., et al. (2014). An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. Biomaterials, 35(34), 9355–9362.PubMedCrossRef Chen, Q., et al. (2014). An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. Biomaterials, 35(34), 9355–9362.PubMedCrossRef
110.
go back to reference Huo, D., et al. (2014). X-ray CT guided fault-free photothermal ablation of metastatic lymph nodes with ultrafine HER-2 targeting W18O49 nanoparticles. Biomaterials, 35(33), 9155–9166.PubMedCrossRef Huo, D., et al. (2014). X-ray CT guided fault-free photothermal ablation of metastatic lymph nodes with ultrafine HER-2 targeting W18O49 nanoparticles. Biomaterials, 35(33), 9155–9166.PubMedCrossRef
111.
go back to reference Hoffman, R. M. (2015). Application of GFP imaging in cancer. Laboratory Investigation, 95(4), 432–452.PubMedCrossRef Hoffman, R. M. (2015). Application of GFP imaging in cancer. Laboratory Investigation, 95(4), 432–452.PubMedCrossRef
112.
go back to reference Timpson, P., McGhee, E. J., & Anderson, K. I. (2011). Imaging molecular dynamics in vivo–from cell biology to animal models. Journal of Cell Science, 124(Pt 17), 2877–2890.PubMedCrossRef Timpson, P., McGhee, E. J., & Anderson, K. I. (2011). Imaging molecular dynamics in vivo–from cell biology to animal models. Journal of Cell Science, 124(Pt 17), 2877–2890.PubMedCrossRef
113.
go back to reference Naczynski, D. J., et al. (2013). Rare-earth-doped biological composites as in vivo shortwave infrared reporters. Nature Communications, 4, 2199.PubMedCrossRef Naczynski, D. J., et al. (2013). Rare-earth-doped biological composites as in vivo shortwave infrared reporters. Nature Communications, 4, 2199.PubMedCrossRef
115.
go back to reference Naczynski, D. J., et al. (2010). Albumin nanoshell encapsulation of near-infrared-excitable rare-Earth nanoparticles enhances biocompatibility and enables targeted cell imaging. Small (Weinheim an der Bergstrasse, Germany), 6(15), 1631–1640.CrossRef Naczynski, D. J., et al. (2010). Albumin nanoshell encapsulation of near-infrared-excitable rare-Earth nanoparticles enhances biocompatibility and enables targeted cell imaging. Small (Weinheim an der Bergstrasse, Germany), 6(15), 1631–1640.CrossRef
116.
go back to reference Cui, M., et al. (2013). Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv Healthc Mater, 2(9), 1236–1245.PubMedPubMedCentralCrossRef Cui, M., et al. (2013). Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv Healthc Mater, 2(9), 1236–1245.PubMedPubMedCentralCrossRef
117.
118.
go back to reference Zheng, X., et al. (2015). Tracking Cancer Metastasis In Vivo by Using an Iridium-Based Hypoxia-Activated Optical Oxygen Nanosensor. Angewandte Chemie (International ed. in English), 54(28), 8094–8099.CrossRef Zheng, X., et al. (2015). Tracking Cancer Metastasis In Vivo by Using an Iridium-Based Hypoxia-Activated Optical Oxygen Nanosensor. Angewandte Chemie (International ed. in English), 54(28), 8094–8099.CrossRef
119.
go back to reference Molaabasi, F., et al. (2020). Fluorescent Nanoclusters for Imaging of Cells/Stem Cells. Methods in Molecular Biology, 2125, 27–37.PubMedCrossRef Molaabasi, F., et al. (2020). Fluorescent Nanoclusters for Imaging of Cells/Stem Cells. Methods in Molecular Biology, 2125, 27–37.PubMedCrossRef
121.
go back to reference Verry, C., et al., Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci Adv, 2020. 6(29): p. eaay5279. Verry, C., et al., Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci Adv, 2020. 6(29): p. eaay5279.
122.
go back to reference Venditto, V. J., & Szoka, F. C., Jr. (2013). Cancer nanomedicines: So many papers and so few drugs! Advanced Drug Delivery Reviews, 65(1), 80–88.PubMedCrossRef Venditto, V. J., & Szoka, F. C., Jr. (2013). Cancer nanomedicines: So many papers and so few drugs! Advanced Drug Delivery Reviews, 65(1), 80–88.PubMedCrossRef
123.
go back to reference Park, K. (2019). The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 305, 221–222.PubMedCrossRef Park, K. (2019). The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 305, 221–222.PubMedCrossRef
125.
go back to reference D’Mello, S. R., et al. (2017). The evolving landscape of drug products containing nanomaterials in the United States. Nature Nanotechnology, 12(6), 523–529.PubMedCrossRef D’Mello, S. R., et al. (2017). The evolving landscape of drug products containing nanomaterials in the United States. Nature Nanotechnology, 12(6), 523–529.PubMedCrossRef
126.
go back to reference Gradishar, W. J., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23(31), 7794–7803.PubMedCrossRef Gradishar, W. J., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23(31), 7794–7803.PubMedCrossRef
127.
go back to reference Gabizon, A., et al. (1994). Clinical studies of liposome-encapsulated doxorubicin. Acta Oncologica, 33(7), 779–786.PubMedCrossRef Gabizon, A., et al. (1994). Clinical studies of liposome-encapsulated doxorubicin. Acta Oncologica, 33(7), 779–786.PubMedCrossRef
128.
go back to reference Nanobiotix, Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval. 2019. Nanobiotix, Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval. 2019.
130.
go back to reference de Lazaro, I., & Mooney, D. J. (2021). Obstacles and opportunities in a forward vision for cancer nanomedicine. Nature Materials, 20(11), 1469–1479.PubMedCrossRef de Lazaro, I., & Mooney, D. J. (2021). Obstacles and opportunities in a forward vision for cancer nanomedicine. Nature Materials, 20(11), 1469–1479.PubMedCrossRef
132.
133.
go back to reference Russell, L.M., C.H. Liu, and P. Grodzinski, Nanomaterials innovation as an enabler for effective cancer interventions. Biomaterials, 2020. 242: p. 119926. Russell, L.M., C.H. Liu, and P. Grodzinski, Nanomaterials innovation as an enabler for effective cancer interventions. Biomaterials, 2020. 242: p. 119926.
134.
go back to reference Pharmaceuticals, A., Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe. 2018. Pharmaceuticals, A., Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe. 2018.
135.
go back to reference Grodzinski, P., et al. (2019). Integrating Nanotechnology into Cancer Care. ACS Nano, 13(7), 7370–7376.PubMedCrossRef Grodzinski, P., et al. (2019). Integrating Nanotechnology into Cancer Care. ACS Nano, 13(7), 7370–7376.PubMedCrossRef
136.
go back to reference Hare, J. I., et al. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108, 25–38.PubMedCrossRef Hare, J. I., et al. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108, 25–38.PubMedCrossRef
137.
go back to reference Hartshorn, C. M., et al. (2018). Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 12(1), 24–43.PubMedCrossRef Hartshorn, C. M., et al. (2018). Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 12(1), 24–43.PubMedCrossRef
138.
go back to reference Schoenmaker, L., et al., mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm, 2021. 601: p. 120586. Schoenmaker, L., et al., mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm, 2021. 601: p. 120586.
Metadata
Title
Nanotechnology-aided advancement in the combating of cancer metastasis
Authors
Leela Rani Avula
Piotr Grodzinski
Publication date
02-04-2022
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-022-10025-7

Other articles of this Issue 2/2022

Cancer and Metastasis Reviews 2/2022 Go to the issue

Announcement

Biographies

EditorialNotes

Preface

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine